Pfizer Aktie
24,87
EUR
-0,14
EUR
-0,56
%
26,08
USD
-0,35
USD
-1,32
%
Kursziele der Pfizer-Aktie in USD
Das durchschnittliche Kursziel beinhaltet alle Analysen eines Analysten und nicht nur die jeweils aktuellste Analyse, die im Chart dargestellt wird.
Diese Analysten bewerten die Pfizer-Aktie
| Analyst | Kursziel | Abstand Kursziel | Datum | |
|---|---|---|---|---|
| DZ BANK | - | - | 05.02.2025 | |
| Goldman Sachs Group Inc. | 32,00 USD | +22,51% | 05.02.2025 | |
| UBS AG | 28,00 USD | +7,20% | 05.02.2025 | |
| JP Morgan Chase & Co. | 30,00 USD | +14,85% | 05.02.2025 | |
| Jefferies & Company Inc. | 33,00 USD | +26,34% | 04.02.2025 | |
| Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | 29,00 USD | +11,03% | 29.11.2024 |
Werbung
Kursziele im Branchenvergleich
| Aktie | Buy | Hold | Sell | Ø Kursziel | Abst. Kursziel |
|---|---|---|---|---|---|
| Abbott Laboratories | 0 | 0 | 0 | - | - |
| Alexion Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Allergan Inc. | 0 | 0 | 0 | - | - |
| APONTIS PHARMA | 0 | 0 | 0 | - | - |
| AstraZeneca PLC | 6 | 3 | 0 | 139,58 GBP | +17,25% |
| Bayer | 1 | 8 | 0 | 24,12 EUR | +0,67% |
| Celgene Corp. | 0 | 0 | 0 | - | - |
| EVOTEC SE | 2 | 2 | 1 | 9,68 EUR | +18,63% |
| Gilead Sciences Inc. | 0 | 0 | 0 | - | - |
| GSK PLC Registered Shs | 2 | 6 | 1 | 16,62 GBP | +12,34% |
| Johnson & Johnson | 0 | 0 | 0 | - | - |
| Merck Co. | 0 | 0 | 0 | - | - |
| Merck KGaA | 7 | 1 | 0 | 183,14 EUR | +32,14% |
| MorphoSys | 0 | 1 | 0 | 68,00 EUR | - |
| Mylan N.V. | 0 | 0 | 0 | - | - |
| Novartis AG | 3 | 5 | 1 | 99,12 CHF | +0,20% |
| Perrigo Company | 0 | 0 | 0 | - | - |
| Pfizer Inc. | 3 | 3 | 0 | 30,40 USD | +16,43% |
| Roche Holding AG (Inhaberaktie) | 0 | 0 | 0 | - | - |
| Sanofi S.A. | 6 | 2 | 0 | 114,14 EUR | +6,16% |
| STADA | 0 | 0 | 0 | - | - |
| Teva Pharmaceutical Industries Ltd. (spons. ADRs) | 0 | 0 | 0 | - | - |
| Vertex Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Warner Chilcott plc | 0 | 0 | 0 | - | - |